Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Acquired by Perigon Wealth Management LLC

Perigon Wealth Management LLC grew its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 153.0% in the 4th quarter, HoldingsChannel reports. The firm owned 12,102 shares of the company’s stock after acquiring an additional 7,319 shares during the quarter. Perigon Wealth Management LLC’s holdings in Amphastar Pharmaceuticals were worth $749,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in shares of Amphastar Pharmaceuticals by 1.1% in the third quarter. BlackRock Inc. now owns 7,147,813 shares of the company’s stock valued at $200,854,000 after purchasing an additional 75,616 shares during the period. Federated Hermes Inc. increased its holdings in Amphastar Pharmaceuticals by 0.7% during the first quarter. Federated Hermes Inc. now owns 3,487,430 shares of the company’s stock worth $125,199,000 after buying an additional 23,095 shares during the last quarter. Vanguard Group Inc. boosted its position in Amphastar Pharmaceuticals by 1.8% during the third quarter. Vanguard Group Inc. now owns 2,606,162 shares of the company’s stock worth $73,234,000 after purchasing an additional 45,385 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Amphastar Pharmaceuticals by 2.7% in the first quarter. Dimensional Fund Advisors LP now owns 1,917,571 shares of the company’s stock valued at $71,909,000 after acquiring an additional 51,027 shares during the period. Finally, State Street Corp raised its stake in Amphastar Pharmaceuticals by 16.6% in the second quarter. State Street Corp now owns 1,540,846 shares of the company’s stock valued at $53,606,000 after purchasing an additional 218,895 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Trading Down 1.3 %

Shares of AMPH opened at $39.62 on Monday. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of 15.36, a PEG ratio of 0.94 and a beta of 0.84. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.17 and a quick ratio of 1.70. Amphastar Pharmaceuticals, Inc. has a 1-year low of $35.62 and a 1-year high of $67.66. The company has a 50-day moving average of $47.31 and a 200 day moving average of $51.39.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing the consensus estimate of $0.84 by ($0.03). The firm had revenue of $178.11 million during the quarter, compared to analyst estimates of $174.90 million. Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. On average, research analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.42 EPS for the current year.

Insider Buying and Selling at Amphastar Pharmaceuticals

In related news, Director Michael A. Zasloff sold 12,500 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total transaction of $589,750.00. Following the completion of the transaction, the director now directly owns 21,326 shares in the company, valued at approximately $1,006,160.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Michael A. Zasloff sold 12,500 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total value of $589,750.00. Following the completion of the sale, the director now owns 21,326 shares of the company’s stock, valued at $1,006,160.68. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Floyd F. Petersen sold 500 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $53.10, for a total transaction of $26,550.00. Following the transaction, the director now directly owns 80,333 shares of the company’s stock, valued at approximately $4,265,682.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 14,000 shares of company stock valued at $660,860. Insiders own 28.40% of the company’s stock.

Analyst Upgrades and Downgrades

AMPH has been the topic of a number of research analyst reports. JPMorgan Chase & Co. started coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 5th. They set an “overweight” rating and a $60.00 price objective on the stock. StockNews.com cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, April 10th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $66.00.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.